Biologics in Pediatric Rheumatology: Quo Vadis?
- PMID: 27306623
- DOI: 10.1007/s11926-016-0593-9
Biologics in Pediatric Rheumatology: Quo Vadis?
Abstract
The past two decades have brought immense satisfaction to pediatric rheumatologists and families of children with rheumatologic diseases. We have been able to better classify, recognize, and diagnose rheumatologic diseases, but most importantly, the discovery of biologic therapies and their efficacy and relative safety in treating multiple rheumatologic conditions, improving quality of life for the patients we care for. We will review the advances of the past two decades and discuss potential areas for new discoveries.
Keywords: Abatacept; IL-1 inhibitors; IL-6 inhibitors; Juvenile idiopathic arthritis (JIA); Rituximab; TNF inhibitors; Tofacitinib.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
